Does growth hormone supplementation of in vitro fertilization/intracytoplasmic sperm injection improve cumulative live birth rates in women with poor embryonic development in the previous cycle?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101153627 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7827 (Electronic) Linking ISSN: 14777827 NLM ISO Abbreviation: Reprod Biol Endocrinol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2003-
    • Subject Terms:
      Sperm Injections, Intracytoplasmic*/methods ; Fertilization in Vitro*/methods ; Live Birth*/epidemiology ; Birth Rate*; Humans ; Female ; Adult ; Pregnancy ; Retrospective Studies ; Embryonic Development/drug effects ; Pregnancy Rate ; China/epidemiology ; Growth Hormone/administration & dosage ; Human Growth Hormone/administration & dosage ; Cohort Studies
    • Abstract:
      Background: Growth hormone (GH) has been proposed as an adjunct in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, especially in women with poor ovarian response. However, it is unclear whether GH supplementation is effective in women with poor embryonic development in the previous IVF cycle. The aim of this study was to evaluate the effectiveness of GH supplementation in IVF/ICSI cycles in women with poor embryonic development in the previous cycle.
      Methods: This is a retrospective cohort study from a public fertility center in China, in which we performed propensity score-matching (PSM) for female age and AFC in a ratio of 1:1. We compared the cumulative live birth rate per started cycle, as well as a series of secondary outcomes. We included 3,043 women with poor embryonic development in the previous IVF/ICSI cycle, of which 1,326 had GH as adjuvant therapy and 1,717 had not. After PSM, there were 694 women in each group.
      Results: After PSM, multivariate analyses showed the cumulative live birth rate to be significantly higher in the GH group than the control group [N = 694, 34.7% vs. N = 694, 27.5%, risk ratio (RR): 1.4 (95%CI: 1.1-1.8)]. Endometrial thickness, number of oocytes retrieved, number of embryos available, and number of good-quality embryos were significantly higher in the GH group compared to controls. Pregnancy outcomes in terms of birth weight, gestational age, fetal sex, preterm birth rate, and type of delivery were comparable. When we evaluated the impact of GH on different categories of female age, the observed benefit in the GH group did not appear to be significant. When we assessed the effect of GH in different AFC categories, the effect of GH was strongest in women with an AFC5-6 (32.2% versus 19.5%; RR 2.0; 95% CI 1.2-3.3).
      Conclusions: Women with poor embryonic quality in the previous IVF/ICSI cycles have higher rates of cumulative live birth with GH supplementation.
      (© 2024. The Author(s).)
    • References:
      Cochrane Database Syst Rev. 2021 Nov 22;11:CD000099. (PMID: 34808697)
      Front Endocrinol (Lausanne). 2019 Nov 12;10:777. (PMID: 31781044)
      J Assist Reprod Genet. 2014 Dec;31(12):1635-41. (PMID: 25326318)
      Int J Endocrinol. 2014;2014:234014. (PMID: 25580121)
      Fertil Steril. 2020 Apr;113(4):811-817. (PMID: 32147171)
      BMC Pregnancy Childbirth. 2020 May 20;20(1):310. (PMID: 32434490)
      Fertil Steril. 2012 Jun;97(6):1338-42. (PMID: 22464083)
      J Endocrinol. 1990 Sep;126(3):R1-4. (PMID: 2120380)
      J Assist Reprod Genet. 2016 Mar;33(3):367-371. (PMID: 26749386)
      Endocrinology. 2002 Oct;143(10):4104-12. (PMID: 12239122)
      Gynecol Endocrinol. 2019 Sep;35(9):787-791. (PMID: 30907187)
      Gynecol Endocrinol. 2015 Jul;31(7):565-8. (PMID: 26193891)
      J Assist Reprod Genet. 2019 Feb;36(2):223-228. (PMID: 30362054)
      J Reprod Med. 2016 Jan-Feb;61(1-2):78-82. (PMID: 26995894)
      Biochem Biophys Res Commun. 2000 Feb 5;268(1):36-41. (PMID: 10652208)
      Reprod Biomed Online. 2010 Jul;21(1):37-49. (PMID: 20457541)
      Reprod Biol Endocrinol. 2020 Dec 7;18(1):121. (PMID: 33287836)
      Reproduction. 2015 Feb;149(2):147-54. (PMID: 25376626)
      Curr Opin Obstet Gynecol. 2017 Jun;29(3):119-125. (PMID: 28306560)
      Reprod Biol Endocrinol. 2020 Sep 30;18(1):97. (PMID: 32998748)
      Gynecol Endocrinol. 2015 Oct;31(10):769-73. (PMID: 26220642)
      Hum Reprod. 2014 Jul;29(7):1444-51. (PMID: 24812313)
    • Grant Information:
      No. 2022SF-565 the General Projects of Social Development in Shaanxi Province
    • Contributed Indexing:
      Keywords: Cumulative live birth rate; Embryo quality; Growth hormone; IVF; Propensity score matching
    • Accession Number:
      9002-72-6 (Growth Hormone)
      12629-01-5 (Human Growth Hormone)
    • Publication Date:
      Date Created: 20240507 Date Completed: 20240508 Latest Revision: 20240510
    • Publication Date:
      20240510
    • Accession Number:
      PMC11075314
    • Accession Number:
      10.1186/s12958-024-01223-9
    • Accession Number:
      38715065